MARKI-MICROWAVE
27.9.2022 08:51:34 CEST | Business Wire | Press release
European Microwave Week – Marki Microwave®, innovator in the radio frequency and microwave industry for over 30 years, today announced the expansion of its millimeter wave (mmWave) portfolio with a series of leading-edge mixers featuring integrated local oscillator (LO) drivers. Ideal for space constrained applications requiring wide bandwidths and operation at mmWave frequencies, the integrated drive mixers reduce size, weight, power and cost (SWaP-C) while simplifying overall integration of the LO path for ease of use and optimized performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005833/en/
Marki Microwave's versatile, broadband double balanced mixers feature an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. (Graphic: Business Wire)
“For customers needing to realize the best performance in a small footprint with reduced design effort, our latest integrated drive mixers are game changers,” said Duncan Pilgrim, vice president of sales and marketing at Marki Microwave. “The designs deliver high performance across a wide bandwidth with reduced drive requirements, promising ease of use in a traditionally complex design space.”
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM are versatile, broadband double balanced mixers featuring an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. Unlike traditional industry solutions using discrete packages, which often suffer from subpar performance, Marki Microwave’s co-packaging utilizes optimal die technology for the amplifier and mixer functions. The new technique eliminates the need for a separate amplifier and mixer interface, minimizing design costs without sacrificing performance across the operating bandwidth. The new integrated drive mixers’ exceptional conversion loss and linearity combined with their compact footprint make the parts an ideal solution for high performance test and measurement, aerospace and defense, telecom infrastructure and satellite designs.
Availability
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM will be available in October in 3 x 4.6 mm QFN packages. Specifications subject to change without notice. For samples and sales information, contact sales@markimicrowave.com.
About Marki Microwave
For over 30 years, Marki Microwave has solved its customers’ most complex problems by creating a robust portfolio of performance shattering RF and microwave components. Founded in 1991 with the goal to develop the best mixers in the industry, Marki Microwave now has the highest performance portfolio of broadband mixers, spanning frequencies from 10 MHz to 130 GHz+ in die, surface mount and connectorized form factors. Today, Marki Microwave is a single source for high performance, broadband microwave products, supporting multiple form factors including die, surface mount and connectorized solutions for the entire RF block diagram. As demands from RF and microwave markets continue to evolve and the supply base consolidates, Marki Microwave remains dedicated to building beyond performance barriers, expanding its catalog and empowering the industry to build next-generation systems. For more information, visit www.markimicrowave.com.
© 2022. Marki Microwave, Inc. All Rights Reserved. Marki Microwave, the Marki logo, and T3 Mixer are trademarks or registered trademarks of Marki Microwave, Inc., in the U.S. and other countries. All other trademarks are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom